AVTR saw its Momentum Indicator move above the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 90 similar instances where the indicator turned positive. In 61 of the 90 cases, the stock moved higher in the following days. The odds of a move higher are at 68%.
The Moving Average Convergence Divergence (MACD) for AVTR just turned positive on October 15, 2026. Looking at past instances where AVTR's MACD turned positive, the stock continued to rise in 30 of 45 cases over the following month. The odds of a continued upward trend are 67%.
Following a +5.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where AVTR advanced for three days, in 172 of 273 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 110 of 174 cases where AVTR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 63%.
The RSI Indicator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AVTR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 73%.
AVTR broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.073) is normal, around the industry mean (4.961). P/E Ratio (-20.306) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (0.840) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (1.614) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. AVTR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 99 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AVTR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
RGEN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 30 of 40 cases where RGEN's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 75%.
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on RGEN as a result. In 63 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
RGEN moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for RGEN crossed bullishly above the 50-day moving average on October 22, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 10 of 17 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 59%.
Following a +2.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where RGEN advanced for three days, in 226 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
The 10-day RSI Indicator for RGEN moved out of overbought territory on September 30, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 25 similar instances where the indicator moved out of overbought territory. In 18 of the 25 cases, the stock moved lower in the following days. This puts the odds of a move lower at 72%.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The Moving Average Convergence Divergence Histogram (MACD) for RGEN turned negative on October 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 42 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 81%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RGEN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for RGEN entered a downward trend on September 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. RGEN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 88 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.775) is normal, around the industry mean (4.961). RGEN's P/E Ratio (241.500) is considerably higher than the industry average of (37.232). Projected Growth (PEG Ratio) (1.935) is also within normal values, averaging (4.143). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (12.469) is also within normal values, averaging (56.876).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RGEN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
AVTR | RGEN | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 31 | 23 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 33 Fair valued | 98 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 93 | 88 | |
PRICE GROWTH RATING 1..100 | 35 | 38 | |
P/E GROWTH RATING 1..100 | 99 | 96 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AVTR's Valuation (33) in the null industry is somewhat better than the same rating for RGEN (98) in the Biotechnology industry. This means that AVTR’s stock grew somewhat faster than RGEN’s over the last 12 months.
AVTR's Profit vs Risk Rating (100) in the null industry is in the same range as RGEN (100) in the Biotechnology industry. This means that AVTR’s stock grew similarly to RGEN’s over the last 12 months.
RGEN's SMR Rating (88) in the Biotechnology industry is in the same range as AVTR (93) in the null industry. This means that RGEN’s stock grew similarly to AVTR’s over the last 12 months.
AVTR's Price Growth Rating (35) in the null industry is in the same range as RGEN (38) in the Biotechnology industry. This means that AVTR’s stock grew similarly to RGEN’s over the last 12 months.
RGEN's P/E Growth Rating (96) in the Biotechnology industry is in the same range as AVTR (99) in the null industry. This means that RGEN’s stock grew similarly to AVTR’s over the last 12 months.
| AVTR | RGEN | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 71% | 1 day ago 72% |
| Stochastic ODDS (%) | 1 day ago 75% | 1 day ago 83% |
| Momentum ODDS (%) | 1 day ago 68% | 1 day ago 70% |
| MACD ODDS (%) | 1 day ago 67% | 1 day ago 81% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 80% |
| TrendMonth ODDS (%) | 1 day ago 67% | 1 day ago 81% |
| Advances ODDS (%) | 2 days ago 63% | 2 days ago 73% |
| Declines ODDS (%) | 16 days ago 73% | 15 days ago 81% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 75% |
| Aroon ODDS (%) | 1 day ago 63% | 2 days ago 86% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AVTR’s FA Score shows that 0 FA rating(s) are green while RGEN’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AVTR’s TA Score shows that 4 TA indicator(s) are bullish while RGEN’s TA Score has 5 bullish TA indicator(s).
AVTR (@Pharmaceuticals: Other) experienced а +9.94% price change this week, while RGEN (@Pharmaceuticals: Other) price change was -2.96% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.74%. For the same industry, the average monthly price growth was -3.62%, and the average quarterly price growth was +9.09%.
AVTR is expected to report earnings on Oct 28, 2026.
RGEN is expected to report earnings on Oct 27, 2026.
Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
A.I.dvisor indicates that over the last year, AVTR has been loosely correlated with RGEN. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if AVTR jumps, then RGEN could also see price increases.
| Ticker / NAME | Correlation To AVTR | 1D Price Change % | ||
|---|---|---|---|---|
| AVTR | 100% | -0.64% | ||
| RGEN - AVTR | 46% Loosely correlated | -0.72% | ||
| BCPC - AVTR | 40% Loosely correlated | +1.43% | ||
| AVNT - AVTR | 38% Loosely correlated | -0.27% | ||
| EMBC - AVTR | 36% Loosely correlated | +2.69% | ||
| ICUI - AVTR | 36% Loosely correlated | +4.66% | ||
More | ||||
A.I.dvisor indicates that over the last year, RGEN has been closely correlated with DHR. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if RGEN jumps, then DHR could also see price increases.
| Ticker / NAME | Correlation To RGEN | 1D Price Change % | ||
|---|---|---|---|---|
| RGEN | 100% | -0.72% | ||
| DHR - RGEN | 67% Closely correlated | -1.76% | ||
| A - RGEN | 65% Loosely correlated | -2.17% | ||
| BIO - RGEN | 60% Loosely correlated | +0.83% | ||
| MTD - RGEN | 59% Loosely correlated | +0.40% | ||
| TMO - RGEN | 58% Loosely correlated | -2.52% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RSP | 218.22 | 1.58 | +0.73% |
| Invesco S&P 500 Equal Weight ETF (RSP) | |||
| MUNX | 23.89 | 0.15 | +0.65% |
| AMG GW&K Muni Income ETF (MUNX) | |||
| BSMQ | 23.43 | 0.02 | +0.09% |
| Invesco BulletShares 2026 Municipal Bond ETF (BSMQ) | |||
| QCJA | 23.77 | -0.21 | -0.88% |
| FT Vest Nasdaq-100 Conservative Buffer ETF - January (QCJA) | |||
| EPOL | 44.12 | -0.96 | -2.13% |
| iShares MSCI Poland ETF (EPOL) | |||